Evolus (STU:EVL) Cyclically Adjusted Revenue per Share: €2.97 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:EVL Evolus Inc STU:EVL
74 GF Score
Price €6.49
GF Value €11.41
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Evolus Cyclically Adjusted Revenue per Share?

Evolus STU:EVL -1.43% 74 Cyclically Adjusted Revenue per Share is €2.97 as of Jun. 2026. GuruFocus rates STU:EVL with a GF Score™ of 74/100 and a GF Value™ of €11.41 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Evolus's adjusted revenue per share for the three months ended in Jun. 2026 was €1.107. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.97 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-11), Evolus's current stock price is €6.488. Evolus's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €2.97. Evolus's Cyclically Adjusted PS Ratio of today is 2.18.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Evolus was 2.23. The lowest was 1.69. And the median was 1.94.


Evolus  (STU:EVL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evolus's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.488/2.97
=2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Evolus was 2.23. The lowest was 1.69. And the median was 1.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Evolus Cyclically Adjusted Revenue per Share Related Terms


Evolus Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Evolus's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus Cyclically Adjusted Revenue per Share Chart

Evolus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Evolus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.97

STU:EVL vs EBS, ELTP, AKBA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evolus's Cyclically Adjusted PS Ratio falls into.


STU:EVL
74GF Score
Evolus Inc STU:EVL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolus Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evolus's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.107/333.9520*333.9520
=1.107

Current CPI (Jun. 2026) = 333.9520.

Evolus Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 236.525 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 0.075 256.143 0.098
201909 0.435 256.759 0.566
201912 0.569 256.974 0.739
202003 0.282 258.115 0.365
202006 0.205 257.797 0.266
202009 0.444 260.280 0.570
202012 0.501 260.474 0.642
202103 0.250 264.877 0.315
202106 0.423 271.696 0.520
202109 0.412 274.310 0.502
202112 0.551 278.802 0.660
202203 0.552 287.504 0.641
202206 0.627 296.311 0.707
202209 0.609 296.808 0.685
202212 0.732 296.797 0.824
202303 0.690 301.836 0.763
202306 0.800 305.109 0.876
202309 0.822 307.789 0.892
202312 0.977 306.746 1.064
202403 0.928 312.332 0.992
202406 0.991 314.175 1.053
202409 0.872 315.301 0.924
202412 1.190 315.605 1.259
202503 0.995 319.799 1.039
202506 0.932 322.561 0.965
202509 0.908 324.800 0.934
202512 1.188 324.054 1.224
202603 0.971 330.213 0.982
202606 1.107 333.952 1.107

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.97 mean?
Evolus (STU:EVL) has a Cyclically Adjusted Revenue per Share of €2.97 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evolus and its competitors.
Is Evolus' Cyclically Adjusted Revenue per Share too high?
Evolus' current Cyclically Adjusted Revenue per Share is €2.97. Overall, Evolus has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Cyclically Adjusted Revenue per Share compare to EBS and ELTP?
Evolus' Cyclically Adjusted Revenue per Share of €2.97 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Evolus and its competitors. Evolus's current Cyclically Adjusted Revenue per Share is €2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (STU:EVL) is currently considered Possible Value Trap. The stock's GF Value™ is €11.41, compared to a current price of €6.49 — trading 43.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.97. Evolus' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Evolus (STU:EVL), the current Cyclically Adjusted Revenue per Share is €2.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (STU:EVL) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of €6.49 is trading 43.1% below its estimated GF Value™ of €11.41. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for STU:EVL:

  • Cyclically Adjusted Revenue per Share: €2.97
  • GF Value™: €11.41 vs. price of €6.49 (43.1% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the STU:EVL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evolus Business Description

Other Exchanges EOLS:USA
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
74GF Score

Get the complete analysis for STU:EVL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.49
Price
€11.41
GF Value